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Copyright © 200? JCBN Summary We investigated energy expenditure in hospitalized patients with Crohn’s disease
(CD), and determined optimal energy requirements for nutritional therapy. Sixteen patients (5
women and 11 men, mean age 36 year old, mean BMI 18.7 kg/m2) and 8 healthy volunteers
were enrolled in this study. Measured resting energy expenditure (mREE) levels were
determined by indirect calorimetry. The mREEs in CD patients were significantly higher than
those of healthy controls (24.4 ± 2.4 kcal/kg/day vs 21.3 ± 1.7 kcal/kg/day). However, mREEs in
CD patients were significantly lower than predicted REEs (pREEs) calculated by the Harris-
Benedict equation (26.4 ± 2.5 kcal/kg/day). Furthermore, mREE/pREE values were lower in
undernourished patients than in well-nourished patients. CD patients had hyper-metabolic
statuses evaluated by mREE/body weight, but increased energy expenditure did not contribute
to weight loss in these patients. In conclusion, nutritional therapy with 25–30 kcal/ideal body
weight/day (calculated by mREE × active factor) may be optimal for active CD patients, while
higher energy intake values pose the risk of overfeeding.
Key Words:Crohn’s disease, resting energy expenditure, indirect calorimetry
Introduction
Crohn’s disease (CD) is a chronic inflammatory disease of
the digestive tract of unknown etiology. Patients with CD are
accompanied by various nutrition deficiencies. Body weight
loss and malnutrition are common features, and nutritional
deficiencies occur in CD patients in both active and remis-
sion phases. Emaciation is found in 20–75% of patients with
CD [1,  2], and approximately 75% of hospitalized CD
patients are undernourished [3,  4]. Malnutrition in CD
patients is associated with decreased dietary intake, malab-
sorption, and protein-losing enteropathy. Furthermore, micro-
nutrient deficiencies including vitamin D, vitamin B12, folic
acid, zinc and selenium are frequent in these patients [5–8].
Nutritional support is essential for CD patients, and nutri-
tional therapy such as enteral nutrition (EN) or total
parenteral nutrition (TPN) has been established as primary
therapy for CD as well as infliximab therapy and steroid
therapy. Especially, elemental diet therapies are effective in
both induction and maintenance therapies [9–11], although
their therapeutic mechanisms are still unknown.
Energy metabolism changes to a hyper-metabolic status in
CD patients [12–16]. However, Melchior et al. [17] reported
that measured REE (mREE) was approximately 33 kcal/kg/
day in patients with CD, which was lower than the REE
observed in other diseases. Furthermore, Schneeweiss et al.
[18] reported that mREE was not significantly different
between CD patients and healthy subjects. In Japan,
nutritional therapies such as EN or TPN therapies are widely
accepted, but energy metabolism in Japanese patients with
CD remains unclear. Total energy of EN or TPN is usually
determined by using predicted resting energy expenditure
(pREE) calculated by the Harris-Benedict equation [19], and
total energy requirements are calculated by pREE × active
factor × stress factor [20]. On the other hand, mREE can beEnergy Metabolism and Crohn’s Disease
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determined by indirect calorimetry. Theoretically, pREE is
equal to mREE in healthy humans, and mREE/pBEE ratios
are markers of hyper-metabolic status.
In this study, we evaluated energy metabolism in Japanese
patients with CD and suggested optimal energy require-
ments for nutritional therapies.
Subjects and Methods
Patients
Sixteen patients with CD (5 women and 11 men, median
age 36 years old) and 8 healthy volunteers were enrolled in
this study. Patients were admitted to the Gastroenterology
Unit of Shiga University of Medical Science Hospital. The
ethics committee of the Shiga University of Medical Science
approved this study. All patients had the diagnosis of CD
established by radiological, histological, and clinical criteria.
Among these patients, two patients had colitic disease, six
patients had ileal disease and eight patients had ileocolitic
disease. Twelve patients were receiving TPN, and three
patients were receiving elemental diet therapy. Infliximab
therapy has just been started in four patients, and (oral)
prednisone (10–30 mg/day) was taken by five patients.
Indirect calorimetry
mREEs and respiratory quotients (RQ) were measured by
computed open-circuit indirect calorimetery (AE-300S;
Minato Medical Science Co., Osaka, Japan). Indirect
calorimetry (IC) was performed in the hospital room the
morning after a 10-h overnight fasting, but infusion of total
parenteral nutrition solution were kept on going. Period
flow and gas calibration were performed prior to measure-
ments. After resting for a minimum of 30 min, patients were
assessed in a supine position with a facemask. A pump drew
ambient air through a facemask at a constant rate. After
equilibrium was reached for 10 min, respiratory exchange
was performed continuously over 30 min. mREE and RQ
data were obtained every minute.
mREE was calculated from oxygen consumption (VO2)
and carbon dioxide production (VCO2) by the Weir equation
[21].
mREE = (3.94 × VO2 +1 . 1 1× VCO2) × 1.44
Measurement of the RQ was calculated as RQ = VCO2/
VO2. The measured mREE was compared with pREE calcu-
lated by the Harris and Benedict equation.
Man; pREE = 66.47 + 13.75 × W + 5.0 × H – 6.75 × A
Woman; pREE = 665.09 + 9.56 × W + 1.84 × H – 4.67 × A
Where pREE stands for resting energy expenditure (kcal/
day), W for weight (kg), H for height (cm) and A for age
(years).
Statistical analyses
Differences between groups were analyzed with Kruskal-
Wallis tests. A p value <0.05 was considered to be statisti-
cally significant. Correlations were investigated with
Spearman rank correlation tests.
Results
Patients were not significantly different from control
subjects in age and height, but had significantly lower body
weights, and thus lower BMIs (Table 1). Crohn’s disease
activity index from these patients was 231.3 ± 84.8, and C-
reactive protein was 3.24 ± 4.6 mg/dl. Average Hemoglobin,
Table 1. Characteristics, energy expenditure and respiratory quotient (RQ) in CD patients (n = 16) and control subjects
(n =8 ) .
BMI; body mass index, pREE; predicted resting energy expenditure calculated by the Harris-Benedict equation. mREE; mea-
sured resting energy expenditure by using indirect calorimetry, RQ; respiratory quotient.
CD patients controls p
Patients number 16 8
Female/male 5/11 2/6
Age (y) 36.0 ± 9.8 44.8 ± 19.0 0.131
Height (cm) 167.8 ± 10.3 165.6 ± 8.1 0.602
Body weight (kg) 52.7 ± 9.4 64.9 ± 12.4 0.013
BMI (kg/mm2) 18.7 ± 2.6 23.5 ± 2.6 <0.001
pREE (kcal/day) 1372.7 ± 143.7 1467.9 ± 238.5 0.233
mREE (kcal/day) 1271.0 ± 181.7 1378.0 ± 253.3 0.245
mREE/pREE (%) 92.5 ± 8.5 94.2 ± 11.4 0.685
pREE/body weight(kcal/kg/day) 26.4 ± 2.5 22.9 ± 2.6 0.003
mREE/body weight(kcal/kg/day) 24.4 ± 2.4 21.3 ± 1.7 0.003
RQ 0.94 ± 0.14 0.85 ± 0.04 0.107M. Sasaki et al.
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red blood cell count, white blood cell count and platelet
count were 10.64 ± 2.1 g/dl, 400.8 ± 62.6 × 104/mm3, 7540 ±
3490/mm2, 35.4 ± 12.2 × 104/mm3 respectively. Serum
albumin and total-cholesterol is 3.46 ± 0.44 g/dl and 127.9 ±
47.6 mg/dl.
In CD patients, mREE determined by indirect calorimetry
was 1271 ± 181.7 kcal/day and pREE calculated by the
Harris-Benedict equation was 1372.7 ± 143.7 kcal/day,
respectively. As shown in Fig. 1, there were significant
correlations between mREE and pREE in CD patients
(p<0.001) as well as in healthy controls (p<0.05). Both
mREE and pREE in CD patients were slightly lower than
those of healthy controls, but there was no significant
difference.
On the other hand, mREE/body weight of CD patients
(24.4 ± 2.4 kcal/kg/day) was significantly higher than that of
healthy control subjects (21.3 ± 1.7 kcal/kg/day) (Table 1).
Similarly, pREE/body weight of CD patients (26.4 ± 2.6
kcal/kg/day) was also significantly higher than that of
healthy control subjects (22.9 ± 2.6 kcal/kg/day) (Table 1).
In CD patients, mREE/body weight was significantly
lower than pREE/body weight (26.4 ± 2.5 kcal/kg/day)
(Fig. 2). Percentage of mREE/pREE was 93.6 ± 13.7% in
CD patients. In only two patients, mREE/body weight was
Fig. 1. Correlation between measured resting energy expendi-
ture (mREE) by indirect calorimetry and predicted rest-
ing energy expenditure (pREE) calculated by the Harris-
Benedict equation in CD patients (n = 16). There is a
positive correlation between mREE and pREE in CD
patients.
Table 2. Energy expenditure and respiratory quotient (RQ) in CD patients (n = 16).
These patients were categorized into two groups based on body mass index 18.5. There are significant differences in BMI,
pREE/body weight between these groups. The mREE/body weight in undernourished CD patients (n = 7) was almost same as
that of well-nourished CD patients (n = 9), and there are no significant differences in pREE, mREE and mREE/pREE value.
BMI; body mass index, pREE; predicted resting energy expenditure calculated by the Harris-Benedict equation. mREE;
measured resting energy expenditure by using indirect calorimetry, RQ; respiratory quotient.
BMI<18.5 BMI>18.5 p
Patients number 7 9
Female/male 3/4 2/7
Age (y) 30.3 ± 2.5 40.0 ± 11.2 0.037
Height (cm) 170.6 ± 11.2 165.6 ± 9.7 0.36
Body weight (kg) 47.7 ± 7.4 56.6 ± 9.3 0.056
BMI (kg/mm2) 16.3 ± 1.2 20.6 ± 1.5 <0.001
pREE (kcal/day) 1327.9 ± 160.1 1407.6 ± 128.1 0.287
mREE (kcal/day) 1173.6 ± 147.9 1347.2 ± 175.2 0.054
mREE/pREE (%) 88.2 ± 1.3 95.8 ± 10.3 0.073
pREE/body weight(kcal/kg/day) 28.0 ± 1.5 25.2 ± 2.5 0.021
mREE/body weight(kcal/kg/day) 24.7 ± 1.2 24.1 ± 3.0 0.615
RQ 0.97 ± 0.12 0.91 ± 0.15 0.422
Fig. 2. Comparison of resting energy expenditure measured by
using indirect calorimetry (mREE) and predicted resting
energy expenditure (pREE) calculated by Harris-
Benedict equation in CD patients (n = 16). mREE is sig-
nificantly lower than pREE in CD patients.Energy Metabolism and Crohn’s Disease
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higher than pBEE/body weight, and one of them developed
complications including an abdominal abscess with fever.
RQ in these patients was 0.94 ± 0.14, and there were
significant positive correlations between mREE and RQ
(Fig. 3), whereas there were no significant correlations
between mREE and RQ in healthy controls (p = 0.075).
However, there were no significant correlations between
mREE and BMI, or between RQ and BMI in CD patients.
Subjects were also categorized into two groups based on
body mass index (group A; <18.5 vs group B; >18.5).
Group A included seven patients and group B included
nine patients. There were no significant differences in
height, body weight, pREE, mREE and between groups,
but there were significant differences in pREE/body weight
(p<0.021). The mREE/body weight in group A (24.7 ± 1.2
kcal/kg/day) was almost same as that of group B (24.1 ± 3.0
kcal/kg/day).
Discussion
This is the first report of resting energy expenditure in
Japanese patients with CD. This study showed that
measured REE by IC in hospitalized CD patients was
24.4 ± 2.4 kcal/kg/day, and this was significantly higher
than that in healthy controls. This result suggests that CD
patients apparently have a hyper-metabolic status, and
supports observations from previous studies [12–16].
However, mREE was significantly lower than pREE calcu-
lated by the Harris-Benedict equation in CD patients.
Usually, energy requirements in hospitalized patients are
calculated by pREE × active factor × stress factor. Stress
factor in patients with inflammatory bowel disease is recom-
mended as 1.1–1.3 [22] as well as in patients with cancer and
chronic obstructive pulmonary disease. This adjustment may
result in the actual energy expenditure as approximately
45 kcal/kg/day. However, Barot et al. reported that the
pBEE was equivalent to mREE in non-septic CD patients.
They decided that energy requirement were often not greater
than the predicted requirement by pREE × active factor ×
stress factor [23]. The inflammatory bowel disease study
group of the Japanese Ministry of Health, Labor and Welfare
also recommends that total energy of TPN or EN should be
40–45 kcal/ideal body weight/day in active CD patients
[24]. However, our study suggests that 30–35 kcal/kg/day
(25–30 kcal/ideal body weight) may be ideal as total energy
for EN or TPN therapies for CD patients by calculating
REE × 1.2–1.3 as the active factor. CD patients certainly
have hyper-metabolic statuses, and but high-energy intakes
during EN or TPN therapies may have a risk of overfeeding.
European guidelines [25] recommend that 25–30 kcal/ideal
body weight/day is optimal for active Crohn’s disease.
A previous study showed that RQ in active CD is signifi-
cant lower than in health controls (CD patients; 0.78 ± 0.05
versus healthy controls; 0.86 ± 0.05) and energy metabolism
in active CD resembled starvation patterns [18]. In this
study, there is a positive correlation between mREE/body
weight and RQ, and this finding shows that fat is mainly
oxidated in low metabolic patients. However, the present
results revealed that (the mean) RQ in hospitalized CD
patients was 0.93 ± 0.14, and there was no significant differ-
ence from that found in controls. Furthermore, there was no
significant difference between RQ and BMI, and RQ was
lower than 0.8 in only a few subjects (12.5%). The afore-
mentioned result may be explained by the fact that our
patients had already received nutritional therapy. Based on
these observations, our results did not support a previous
report that energy metabolism of active CD patients mimic
starvation patterns.
It has long been hypothesized that increased energy
expenditure contributes to weight loss in patients with CD.
However, Vaisman et al. [26] reported that mREE/pREE
was higher in a well-nourished CD group than in an under-
nourished CD group. In this study, mREE/body weight in the
undernourished group was found to be equivalent to that in
well-nourished group, and mREE/pREE was slightly higher
in the well-nourished group than the undernourished group.
These observations support that increased energy expendi-
ture is not a contributor to the underweight status of CD
patients. Mingrone et al. reported that prednisone therapy
did not change energy expenditure, but stimulated food
intake [27]. This means that steroid treatment promotes an
overall positive energy balance. However, patients receiving
this oral steroid were few in this study (31.2%).
Recently, Wise et al. [ 28] reported that REE did not
change after Infliximab therapy, whereas RQ increased after
Infliximab therapy. Their result revealed that lipolysis
decreased and starvation improved in CD patients receiving
Infliximab therapy. Infliximab therapy is now going to be a
main therapeutic tool in active CD patients, but nutritional
management is necessary in these patients. REE and RQ
Fig. 3. Correlation between resting mREE and respiratory
quotient (RQ) in CD patients (n = 16). RQ in CD
patients exhibited a positive correlation with mREE.M. Sasaki et al.
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determinations by indirect calorimetry are useful for CD
patients receiving Infliximab therapy as well as nutritional
therapies.
In conclusion, we determined resting energy expenditure
in Japanese patients with CD. Nutritional therapies consisting
of 25–30 kcal/ideal body weight/day are recommended as
optimal for active CD patients.
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